Please login to the form below

Not currently logged in
Email:
Password:

Dutch companies partner on vaccines

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio. Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

Under the agreement, Immunovo will develop its therapeutic vaccine portfolio. Immunovo will pay an undisclosed cash sum to Pepscan and Pepscan will take a minority interest in Immunovo.

"Pepscan has recently refocused its R&D programme on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides," said Wim Mol, CEO of Pepscan.

"The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research programme. We consider Immunovo an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years."

Joost van Bree, CEO of Immunovo, said: "We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in phase II clinical development.

"We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers."

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration.

28th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics